degarelix accord
accord healthcare s.l.u. - degarelix acetate - nowotwory stercza - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
bronchicum n 0,75 g/5 ml syrop
sanofi-aventis sp. z o.o. - thymi extractum fluidum + thymi extractum fluidum - syrop - 0,75 g/5 ml
bronchicum t 100 mg tabletki do ssania
opella healthcare poland sp. z o.o. - thymi extractum fluidum - tabletki do ssania - 100 mg
neoazarina 316 mg + 10 mg tabletka powlekana
wrocławskie zakłady zielarskie "herbapol" s.a. - thymi herba pulveratum + codeini phosphas - tabletka powlekana - 316 mg + 10 mg
original tymianek i podbiał 100 mg + 100 mg pastylki twarde
perrigo poland sp. z o.o. - thymi extractum fluidum + tussilaginis farfarae folii extractum spissum (4,5 - 6,0:1) ekstarhent - woda do ekstrakcji - pastylki twarde - 100 mg + 100 mg
tymsal-spray - płyn do stosowania w jamie ustnej
krakowskie zakłady zielarskie "herbapol" w krakowie s.a. - thymi extractum fluidum + salviae tinctura - płyn do stosowania w jamie ustnej - -
sallevia 110 mg/ml syrop
conforma nv - thymi extractum fluidum - syrop - 110 mg/ml
bronchostop na kaszel 59,5 mg pastylki miękkie
kwizda pharma gmbh - thymi herba extractum + wyciąg natywny - pastylki miękkie - 59,5 mg
bronchostop duo na kaszel (120 mg + 830 mg)/15 ml syrop
kwizda pharma gmbh - thymi herba extractum siccum + althaeae radicis extractum fluidum - syrop - (120 mg + 830 mg)/15 ml
revolade
novartis europharm limited - olamine - purpura, trombocytopenic, idiopatyczny - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.